Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study

Abstract

Introduction

Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of antineoplastic therapy. The incidence of CIT varies with cancer type and regimen used. CIT can result in chemotherapy delays, dose reductions, and discontinuation, leading to reduced survival rates· Romiplostim is a thrombopoietin receptor agonist that is effective for the treatment of CIT.

Aim

This article evaluates the efficacy and safety of romiplostim in patients with CIT in a real-world setting

Methodology

The study was a retrospective, single-center study, which enrolled patients with solid tumors or hematological malignancies with persistent thrombocytopenia who had been treated with romiplostim.

Results

A total of 100 patients with CIT were categorized into three treatment groups: romiplostim 500 mcg (N = 56), romiplostim 500 mcg + 1-unit random donor platelets (RDP) (N = 35), and romiplostim 500 mcg + 2-unit RDP (N = 9). The most common malignancies were gallbladder carcinoma in the romiplostim 500 mcg group, breast cancer in the romiplostim 500 mcg + 1-unit RDP group (31.4%), and gallbladder and head and neck carcinoma in the romiplostim 500 mcg + 2-unit RDP group. Chemotherapy regimens varied, with gemcitabine + cisplatin (26.7%), Adriamycin + cyclophosphamide (31%), and paclitaxel + carboplatin (22%) being the most used in each group, respectively. Grade I thrombocytopenia was most frequent with Capox (22.2%), grade II with gemcitabine + cisplatin (42.3%), grade III with paclitaxel + carboplatin and gemcitabine + cisplatin (17.02%), and grade IV with paclitaxel + carboplatin (44.4%). Romiplostim significantly increased platelet counts across all groups (p < 0.001), demonstrating its effectiveness in managing CIT across all severity grades.

Conclusion

Romiplostim was effective in increasing platelet counts regardless of the grade of thrombocytopenia. Romiplostim use for the management of CIT will help in correcting CIT and allow resumption of chemotherapy without recurrence of CIT in most patients undergoing cancer chemotherapy.

Keywords

cancer - chemotherapy-induced thrombocytopenia - malignancies - romiplostim - tumor

Publikationsverlauf

Eingereicht: 03. März 2025

Angenommen: 02. Mai 2025

Artikel online veröffentlicht:
18. Juni 2025

• References

• 1 Epstein RS, Aapro MS, Basu Roy UK. et al. Patient burden and real-world Management of Chemotherapy-Induced Myelosuppression: Results from an online survey of patients with solid tumors. Advances in therapy 2020; 37 (08) 3606-3618
• 2 Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica 2021; 106 (04) 1148-1157
• 3 Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021; 106 (05) 662-672
• 4 Schiffer CA, Bohlke K, Delaney M. et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology. Clin Ther 2009; 31 (Pt 2): 2416-2432
• 5 Soff GA, Miao Y, Bendheim G. et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol 2019; 37 (31) 2892-2898
• 6 Song AB, Goodarzi K, Karp Leaf R, Kuter DJ, Al-Samkari H. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. Am J Hematol 2021; 96 (12) 1563-1568
• 7 Perreault S, Burzynski J. Romiplostim: a novel thrombopoiesis-stimulating agent. Am J Health Syst Pharm 2009; 66 (09) 817-824
• 8 Parameswaran R, Lunning M, Mantha S. et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer 2014; 22 (05) 1217-1222
• 9 Al-Samkari H. Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. Blood Rev 2024; 63: 101139